Edwards Lifesciences (EW) Other Non-Current Liabilities (2009 - 2026)

Edwards Lifesciences has reported Other Non-Current Liabilities for 18 years, with the latest figure at $572.2 million in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 35.72% year-over-year to $572.2 million in Q2 2026; TTM through Jun 2026 was $572.2 million, a 35.72% increase from a year earlier, with the FY2025 full-year figure at $502.7 million, up 30.71% from the prior year.
• Other Non-Current Liabilities was $572.2 million for Q2 2026 at Edwards Lifesciences, up from $555.4 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $572.2 million in Q2 2026, with the low at $267.5 million in Q4 2022.
• Average Other Non-Current Liabilities over 5 years is $369.9 million, with a median of $339.9 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Other Non-Current Liabilities increased 0.07% in 2022, then jumped 37.95% in 2026.
• Over 5 years, Other Non-Current Liabilities stood at $267.5 million in 2022, then increased by 25.23% to $335.0 million in 2023, then grew by 14.81% to $384.6 million in 2024, then surged by 30.71% to $502.7 million in 2025, then advanced by 13.83% to $572.2 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $572.2 million (Q2 2026), $555.4 million (Q1 2026), and $502.7 million (Q4 2025), per Business Quant data.